Affiliations: [a] Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China | [b] Nantong University, Nantong, Jiangsu, China | [c] Department of Rheumatology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China | [d] Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
Correspondence:
[*]
Corresponding author: Shaoqing Ju, Department of Laboratory Medicine, Affiliated Hospital of Nantong University, #20 Xisi Road, Nantong, Jiangsu 226001, China. E-mail: jsq814@hotmail.com.
Abstract: Multiple myeloma (MM) is a common hematological malignancy that is often associated with osteolytic lesions, anemia and renal impairment. Deregulation of miRNA has been implicated in the pathogenesis of MM. It was found in our study that miR-19b and miR-20a as members of crucial oncogene miR-17-92 cluster were differentially expressed between patients with MM and normal controls by genechip microarray, and this result was further confirmed in sera of patients with MM by qRT-PCR. The functional effect of miR-19b/20a was analyzed and results showed that miR-19b/20a promoted cell proliferation and migration, inhibited cell apoptosis and altered cell cycle in MM cells. PTEN protein expression was reduced after transfection of miR-19b/20a, suggesting that PTEN was a direct target of miR-19b/20a. In addition, over-expression of miR-19b/20a reversed the anti-proliferation and pro-apoptosis effect of PTEN in MM cells. Finally, our in vivo experiment demonstrated that lentivirus-mediated delivery of miR-20a promoted tumor growth in murine xenograft model of MM, which provide evidence that miR-20a inhibitor exerts therapeutic activity in preclinical models and supports a framework for the development of miR-19b/20a-based treatment strategies for MM patients.
